Biofrontera Amends 8-K on Material Agreement Termination
Ticker: BFRIW · Form: 8-K/A · Filed: Jan 9, 2024 · CIK: 1858685
| Field | Detail |
|---|---|
| Company | Biofrontera INC. (BFRIW) |
| Form Type | 8-K/A |
| Filed Date | Jan 9, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $6.5 m, $150,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: agreement-termination, 8-K/A, corporate-governance
TL;DR
**BFRI amended its 8-K regarding a terminated material agreement; details are sparse but could impact future business.**
AI Summary
Biofrontera Inc. (BFRI) filed an 8-K/A on January 9, 2024, to amend its previous 8-K filing from December 21, 2023. This amendment specifically relates to the termination of a material definitive agreement, though the filing itself does not provide details about the agreement or the termination. This matters to investors because the termination of a significant agreement could impact the company's future revenue streams, operational plans, or strategic direction, potentially affecting the stock's value.
Why It Matters
The termination of a material definitive agreement could signal a change in Biofrontera's business strategy or financial outlook, directly impacting its future profitability and stock performance.
Risk Assessment
Risk Level: medium — The lack of specific details about the terminated agreement creates uncertainty, which is a moderate risk for investors.
Analyst Insight
Investors should monitor Biofrontera Inc.'s future filings and announcements for specific details regarding the terminated material definitive agreement to assess its impact on the company's financial health and strategic direction.
Key Numbers
- $0.001 — Common Stock Par Value (The par value per share of Biofrontera Inc.'s common stock.)
Key Players & Entities
- Biofrontera Inc. (company) — the registrant filing the 8-K/A
- December 21, 2023 (date) — date of the earliest event reported and the original 8-K filing
- January 9, 2024 (date) — date the 8-K/A was filed
- $0.001 (dollar_amount) — par value per share of common stock
Forward-Looking Statements
- Biofrontera Inc. will likely provide more details about the terminated agreement in a future filing or earnings call. (Biofrontera Inc.) — medium confidence, target: Q1 2024
FAQ
What is the purpose of this 8-K/A filing by Biofrontera Inc.?
This 8-K/A filing is an Amendment No. 1 to a previous Current Report on Form 8-K, specifically to provide updated information regarding the termination of a material definitive agreement, with the earliest event reported on December 21, 2023.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on December 21, 2023, which is also the date of the original 8-K filing that this amendment refers to.
What specific item information is covered in this 8-K/A?
The item information covered in this 8-K/A is "Termination of a Material Definitive Agreement."
What is the par value of Biofrontera Inc.'s common stock as mentioned in the filing?
The common stock of Biofrontera Inc. has a par value of $0.001 per share.
What is Biofrontera Inc.'s trading symbol and on which exchange is it registered?
The filing indicates Biofrontera Inc.'s trading symbol is BFRI, and its common stock is registered on an exchange, though the specific exchange name is not provided in the excerpt, only that it is registered pursuant to Section 12(b) of the Exchange Act.
Filing Stats: 599 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-01-09 17:01:41
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Mar
- $6.5 m — that provided for maximum borrowings of $6.5 million, subject to a borrowing base and
- $150,000 — ith the termination, the Company paid a $150,000 prepayment fee to MidCap. As reported i
Filing Documents
- form8-ka.htm (8-K/A) — 44KB
- 0001493152-24-001848.txt ( ) — 269KB
- bfri-20231221.xsd (EX-101.SCH) — 4KB
- bfri-20231221_def.xml (EX-101.DEF) — 27KB
- bfri-20231221_lab.xml (EX-101.LAB) — 37KB
- bfri-20231221_pre.xml (EX-101.PRE) — 25KB
- form8-ka_htm.xml (XML) — 6KB
02 Termination
Item 1.02 Termination of a Material Definitive Agreement Effective as of January 4, 2024, the Company terminated the MidCap Loan Agreement. In connection with the termination, the Company paid a $150,000 prepayment fee to MidCap. As reported in the Original Form 8-K, the Company terminated the MidCap Loan Agreement in connection with entering into Agreement A and Agreement B (each as defined in the Original Form 8-K). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. January 9, 2024 Biofrontera Inc. (Date) (Registrant) /s/ E. Fred Leffler III E. Fred Leffler, III Chief Financial Officer